Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Lymphocytic Leukemia: early-phase trial registry
65 of 189 indexed Chronic Lymphocytic Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #57 of 28,707 conditions by registered trial count.
189 US clinical trials · 65 currently recruiting · #57 of 28,707 conditions by registered trial count
Chronic Lymphocytic Leukemia: 189 US clinical trials tracked, 65 recruiting.
Chronic Lymphocytic Leukemia is the subject of 189 registered US clinical trials on ClinicalTrials.gov, 65 of them currently open to new participants. 27 are in Phase 3-4 (later-stage) and 141 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 15 of these trials.
Enrollment posture brief
Registry condition chronic-lymphocytic-leukemia
OPEN 65 | RECR 34% | LATE 27 | EARLY 141 | RANK #57 | SPON 15
Volume-matched condition peers
Nearest open-share peer: Stage IIIB Lung Cancer AJCC v8 (34% recruiting · 32 trials)
Chronic Lymphocytic Leukemia lists 65 open slots (34% of 189 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Lymphocytic Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Lymphocytic Leukemia is recruiting below its size-band peers.
65 of 189 indexed trials (34.4%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Chronic Lymphocytic Leukemia trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 15 of 189 trials (7.9%). 94 distinct sponsors appear on at least one study for this condition label.
-
Most Chronic Lymphocytic Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 58 among the 188 trials that report a genuine target (sentinel values excluded). 123 of those (65.4%) plan for fewer than 100 participants.
-
Chronic Lymphocytic Leukemia research is mostly interventional.
177 interventional and 12 observational studies make up this index (93.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
189 total, page 1 of 4
Understanding Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
NCT04028531
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Wake Forest University Health Sciences
NCT01890486
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
NCT05334069
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Merck Sharp & Dohme
NCT06136559
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Eli Lilly and Company
NCT06876649
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Janssen Research & Development
NCT01804686
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Loxo Oncology
NCT05254743
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines
NCT06943872
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
BeOne Medicines
NCT05006716
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BeOne Medicines
NCT06973187
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Medical College of Wisconsin
NCT03375619
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Eli Lilly and Company
NCT06876662
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
BeOne Medicines
NCT06846671
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Loxo Oncology
NCT06588478
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
National Cancer Institute (NCI)
NCT04269902
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT06059391
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Emory University
NCT03501576
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT01962636
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
AbbVie
NCT06428019
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
AbbVie
NCT05512390
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
AbbVie
NCT05618028
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Hoffmann-La Roche
NCT05091424
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Imugene Limited
NCT03666000
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
NCT03516617
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Carna Biosciences
NCT05602363
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Curis
NCT07271667
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
VA Office of Research and Development
NCT06520098
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical
NCT04771572
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Mayo Clinic
NCT06151730
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
M.D. Anderson Cancer Center
NCT03128879
Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
University of Utah
NCT04844528
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
Seema Bhat
NCT05417165
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
City of Hope Medical Center
NCT05672355
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
National Heart, Lung, and Blood Institute (NHLBI)
NCT03986034
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Christine Ryan
NCT06043674
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Baylor College of Medicine
NCT01853631
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Jennifer R. Brown, MD, PhD
NCT06644183
Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
NCT05031897
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
Zulfa Omer
NCT07014917
Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial
University of Utah
NCT05183854
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Inhye Ahn
NCT06333262
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT04505254
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
NCT05336812
Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors
Northwell Health
NCT05643235
Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects
Mayo Clinic
NCT06536452
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
OHSU Knight Cancer Institute
NCT06784167
64Cu-LLP2A for Imaging Hematologic Malignancies
Washington University School of Medicine
NCT06636175
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
UNC Lineberger Comprehensive Cancer Center
NCT06860880
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Massachusetts General Hospital
NCT04560322
Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL
Massachusetts General Hospital
NCT06849713
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 67 |
| Phase 2 | 74 |
| Phase 3 | 25 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Lymphocytic Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Lymphocytic Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Lymphocytic Leukemia page
189 registered trials, 65 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 65 Chronic Lymphocytic Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Chronic Lymphocytic Leukemia trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Lymphocytic Leukemia condition card totals 189 registered trials; most-linked intervention Venetoclax; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.